- +971 50 312 9316
- info@menovivreclinic.com
- Mon-Fri: 8AM - 7PM | Sun: 8AM - 4PM
Polycystic Ovary Syndrome (PCOS) is a hormonal and metabolic condition characterised by a combination of:
Transdermal delivery is generally preferred at Menovivre because it bypasses hepatic first-pass metabolism, reducing the risk of blood clots compared to oral oestrogen tablets. This is consistent with guidance from the British Menopause Society and NICE.
PCOS can begin as early as adolescence, with symptoms sometimes appearing around the time of the first period, at approximately 12 years old. At Menovivre, we distinguish carefully between normal pubertal hormonal variability and a pattern that suggests early PCOS or a high-risk trajectory. A thorough history, cycle pattern review, and targeted testing are essential to getting this right.
PCOS is not only a fertility issue. In adolescence, its most significant impact is often on self-esteem, metabolic health, and long-term wellbeing. For a more detailed look, read our guide to PCOS in teenagers.
Transdermal delivery is generally preferred at Menovivre because it bypasses hepatic first-pass metabolism, reducing the risk of blood clots compared to oral oestrogen tablets. This is consistent with guidance from the British Menopause Society and NICE.
The downstream effects are the symptoms most associated with PCOS: acne, hirsutism, hair thinning, and disrupted cycles. Correcting insulin sensitivity through targeted nutrition, supplementation such as myo-inositol and d-chiro-inositol in the physiologically correct 40:1 ratio, and pharmaceutical support where appropriate, directly reduces androgen excess. The NICE guidelines on PCOS recognise insulin sensitising agents as a primary therapeutic pathway for this reason.
At Menovivre, we assess total testosterone, free testosterone, DHEA-S, and SHBG as part of our initial diagnostics. Treating androgen excess without identifying its origin, whether ovarian, adrenal, or insulin-driven, is unlikely to produce lasting results.
Our functional medicine specialist, leads the hormonal and metabolic assessment, identifies root causes, and builds your personalised treatment strategy including lifestyle medicine, advanced testing, supplementation, and hormonal support.
Our Gynaecology specialist assesses menstrual irregularity, ovulation, fertility concerns, ultrasound findings, and gynaecological differentials that may overlap with PCOS.
Designs sustainable nutrition strategies for insulin resistance, inflammation, weight regulation, and cycle support. For many women, nutrition is the foundation of the entire treatment plan.
The First Three Months
Most women notice meaningful improvements in cycle regularity, energy, and mood stability. Skin changes often begin to appear as androgen levels correct, and improvements in appetite regulation and weight management typically become evident within this window.
Three to Six Months
Cycle regularity consolidates, libido often improves, and many women report clearer cognitive and emotional steadiness. Hirsutism responds more slowly, as hair follicles operate on a three to six month cycle.
Long-Term
Correcting insulin resistance, managing androgen excess, and sustaining hormonal balance significantly reduces your lifetime risk of type 2 diabetes, cardiovascular disease, and endometrial hyperplasia. This is the investment that matters most.
A: PCOS cannot be cured in the conventional sense, but it can be managed effectively to the point where symptoms are minimal or absent. The goal at Menovivre is root-cause correction, which often produces lasting results rather than indefinite dependency on medication.
A: Yes. Despite its name, cysts are not required for a PCOS diagnosis. Under the Rotterdam Criteria, you need to meet only two of three markers. Many women are diagnosed on hormonal and clinical findings alone.
A: A thorough panel should include LH and FSH ratio, oestradiol, total and free testosterone, DHEA-S, SHBG, AMH, fasting insulin, fasting glucose, HbA1c, thyroid function, liver enzymes, and a full lipid panel. Many standard referrals test only a fraction of these.
A: It changes rather than straightforwardly worsening. Declining oestrogen during perimenopause alters the hormonal picture significantly, and new symptoms can emerge alongside existing ones. Women with PCOS also carry a higher baseline metabolic risk, making proactive management through this transition particularly important.
A: No. The pill masks symptoms without addressing the underlying condition and is not suitable for women trying to conceive. Effective alternatives include insulin-sensitising therapies, targeted supplementation, nutritional medicine, and hormonal optimisation protocols.
A: Yes. Unmanaged PCOS is associated with a significantly elevated risk of type 2 diabetes, cardiovascular disease, endometrial hyperplasia, and non-alcoholic fatty liver disease. Long-term metabolic and cardiovascular protection is a core part of the care we provide.
A: Yes. Early assessment is valuable, and the sooner a pattern is identified, the more effectively it can be managed. Our team is experienced in assessing adolescent presentations carefully, distinguishing between normal pubertal variation and early PCOS, and building an age-appropriate plan from the outset.
